Literature DB >> 25496873

Carriers of a common variant in the dopamine transporter gene have greater dementia risk, cognitive decline, and faster ventricular expansion.

Florence F Roussotte1, Boris A Gutman2, Derrek P Hibar2, Sarah K Madsen2, Katherine L Narr3, Paul M Thompson4.   

Abstract

INTRODUCTION: Genetic variants in DAT1, the gene encoding the dopamine transporter (DAT) protein, have been implicated in many brain disorders. In a recent case-control study of Alzheimer's disease (AD), a regulatory polymorphism in DAT1 showed a significant association with the clinical stages of dementia.
METHODS: We tested whether this variant was associated with increased AD risk, and with measures of cognitive decline and longitudinal ventricular expansion, in a large sample of elderly participants with genetic, neurocognitive, and neuroimaging data from the Alzheimer's Disease Neuroimaging Initiative.
RESULTS: The minor allele-previously linked with increased DAT expression in vitro-was more common in AD patients than in both individuals with mild cognitive impairment and healthy elderly controls. The same allele was also associated with poorer cognitive performance and faster ventricular expansion, independently of diagnosis. DISCUSSION: These results may be due to reduced dopaminergic transmission in carriers of the DAT1 mutation.
Copyright © 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DAT1; Dementia; Dopamine transporter; Neuroimaging genetics; Ventricular expansion

Mesh:

Substances:

Year:  2014        PMID: 25496873      PMCID: PMC4465053          DOI: 10.1016/j.jalz.2014.10.011

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  68 in total

1.  Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.

Authors:  M A Piggott; E F Marshall; N Thomas; S Lloyd; J A Court; E Jaros; D Burn; M Johnson; R H Perry; I G McKeith; C Ballard; E K Perry
Journal:  Brain       Date:  1999-08       Impact factor: 13.501

2.  Global prevalence of dementia: a Delphi consensus study.

Authors:  Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

3.  Synergistic requirements for the induction of dopaminergic D1/D5-receptor-mediated LTP in hippocampal slices of rat CA1 in vitro.

Authors:  Sheeja Navakkode; Sreedharan Sajikumar; Julietta Uta Frey
Journal:  Neuropharmacology       Date:  2007-03-12       Impact factor: 5.250

4.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

5.  Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Authors:  K A Conway; J C Rochet; R M Bieganski; P T Lansbury
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

6.  Rotigotine protects against glutamate toxicity in primary dopaminergic cell culture.

Authors:  Sandra Oster; Khaled Radad; Dieter Scheller; Marlen Hesse; Wladimir Balanzew; Heinz Reichmann; Gabriele Gille
Journal:  Eur J Pharmacol       Date:  2013-12-21       Impact factor: 4.432

7.  Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine.

Authors:  M J LaVoie; T G Hastings
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

8.  Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease.

Authors:  Pietro Tiraboschi; Larry A Hansen; Michael Alford; Annette Merdes; Eliezer Masliah; Leon J Thal; Jody Corey-Bloom
Journal:  Arch Gen Psychiatry       Date:  2002-10

9.  Probability, proof, and clinical significance.

Authors:  Andrea C Skelly
Journal:  Evid Based Spine Care J       Date:  2011-11

10.  Positive FP-CIT SPECT (DaTSCAN) in Clinical Alzheimer's Disease - An Unexpected Finding?

Authors:  Verena Bittner; Gerhard Ullrich; Markus Thormann; Notger G Müller; Christin Friederichs; Holger Amthauer; Hans-Jochen Heinze; Daniel M Bittner
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2011-09-21
View more
  7 in total

Review 1.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

Review 2.  Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.

Authors:  Andrew J Saykin; Li Shen; Xiaohui Yao; Sungeun Kim; Kwangsik Nho; Shannon L Risacher; Vijay K Ramanan; Tatiana M Foroud; Kelley M Faber; Nadeem Sarwar; Leanne M Munsie; Xiaolan Hu; Holly D Soares; Steven G Potkin; Paul M Thompson; John S K Kauwe; Rima Kaddurah-Daouk; Robert C Green; Arthur W Toga; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

3.  Combinatorial model of amyloid β and tau reveals synergy between amyloid deposits and tangle formation.

Authors:  Emily J Koller; Kristen R Ibanez; Quan Vo; Karen N McFarland; Elsa Gonzalez De La Cruz; Lillian Zobel; Tristan Williams; Guilian Xu; Daniel Ryu; Preya Patel; Benoit I Giasson; Stefan Prokop; Paramita Chakrabarty
Journal:  Neuropathol Appl Neurobiol       Date:  2021-12-10       Impact factor: 8.090

4.  Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Olaia Martínez-Iglesias; Lola Corzo; Natalia Cacabelos; Rocío Pego; Juan C Carril
Journal:  Methods Mol Biol       Date:  2022

Review 5.  Parkinson disease-associated cognitive impairment.

Authors:  Dag Aarsland; Lucia Batzu; Glenda M Halliday; Gert J Geurtsen; Clive Ballard; K Ray Chaudhuri; Daniel Weintraub
Journal:  Nat Rev Dis Primers       Date:  2021-07-01       Impact factor: 52.329

Review 6.  The DRD2 Taq1A A1 Allele May Magnify the Risk of Alzheimer's in Aging African-Americans.

Authors:  Kenneth Blum; Rajendra D Badgaiyan; Georgia M Dunston; David Baron; Edward J Modestino; Thomas McLaughlin; Bruce Steinberg; Mark S Gold; Marjorie C Gondré-Lewis
Journal:  Mol Neurobiol       Date:  2017-09-30       Impact factor: 5.590

7.  Risk Variants in Three Alzheimer's Disease Genes Show Association with EEG Endophenotypes.

Authors:  Ana Macedo; Carlos Gómez; Miguel Ângelo Rebelo; Jesús Poza; Iva Gomes; Sandra Martins; Aarón Maturana-Candelas; Víctor Gutiérrez-de Pablo; Luis Durães; Patrícia Sousa; Manuel Figueruelo; María Rodríguez; Carmen Pita; Miguel Arenas; Luis Álvarez; Roberto Hornero; Alexandra M Lopes; Nádia Pinto
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.